Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 2/2024

27.12.2023 | Gynecologic Endocrinology and Reproductive Medicine

A comparison of the effects of oral dydrogesterone and levonorgestrel-releasing intrauterine device on quality of life and sexual function in patients with abnormal uterine bleeding

verfasst von: Ruken Abul, Nura Fitnat Topbas Selcuki, Ozan Karadeniz, Pınar Yalçın Bahat

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Objective

The purpose of this study is to compare the effects of cyclic oral dydrogesterone treatment and levonorgestrel-releasing intrauterine device (LNG_IUD) on quality of life (QoL) and sexual function in patients diagnosed with abnormal uterine bleeding (AUB).

Study design

The study was conducted at the University of Health Sciences Turkey Health Istanbul Kanuni Sultan Süleyman Training and Research Hospital, on 171 sexually active patients, aged 18–45, who were under a minimum of 6 months of treatment for AUB. 85 patients were treated with oral cyclic dydrogesterone, and 86 patients received LNG-IUD. Following a minimum of 6 months of treatment, these patients were recruited to the study and were asked to complete a 36-Item Short Form Survey (SF-36) and the Female Sexual Function Index (FSFI).

Results

When the FSFI scores of the patients were compared, it was observed that the total FSFI score was significantly higher in the cyclic dydrogesterone group (p < 0.05). Likewise, it was observed that sexual desire, arousal, and lubrication domains were significantly higher in the cyclic dydrogesterone group (p < 0.05). No significant differences were found between the treatment groups in 7 out of the 8 dimensions of SF-36. The energy/vitality dimension was found to be significantly higher in the cyclic dydrogesterone group.

Conclusion

Total FSFI score, as well as sexual desire, arousal, and lubrication scores, were significantly higher in the cyclic dydrogesterone group compared to the LNG-IUD group indicating that cyclic dydrogesterone has a more positive impact on sexual function when compared to LNG-IUD.
Literatur
1.
Zurück zum Zitat Matthews ML (2015) Abnormal uterine bleeding in reproductive-aged women. Obstet Gynecol Clin North Am 42(1):103–115CrossRefPubMed Matthews ML (2015) Abnormal uterine bleeding in reproductive-aged women. Obstet Gynecol Clin North Am 42(1):103–115CrossRefPubMed
2.
Zurück zum Zitat Munro MG, Critchley HO, Broder MS, Fraser IS (2011) FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet 113(1):3–13CrossRefPubMed Munro MG, Critchley HO, Broder MS, Fraser IS (2011) FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet 113(1):3–13CrossRefPubMed
3.
Zurück zum Zitat Marnach ML, Laughlin-Tommaso SK (2019) Evaluation and management of abnormal uterine bleeding. Mayo Clin Proc 94(2):326–335CrossRefPubMed Marnach ML, Laughlin-Tommaso SK (2019) Evaluation and management of abnormal uterine bleeding. Mayo Clin Proc 94(2):326–335CrossRefPubMed
4.
Zurück zum Zitat Liu Z, Doan QV, Blumenthal P, Dubois RW (2007) A systematic review evaluating health-related quality of life, work impairment, and health-care costs and utilization in abnormal uterine bleeding. Value Health 10(3):183–194CrossRefPubMed Liu Z, Doan QV, Blumenthal P, Dubois RW (2007) A systematic review evaluating health-related quality of life, work impairment, and health-care costs and utilization in abnormal uterine bleeding. Value Health 10(3):183–194CrossRefPubMed
5.
Zurück zum Zitat Heliövaara-Peippo S, Hurskainen R, Teperi J, Aalto AM, Grénman S, Halmesmäki K et al (2013) Quality of life and costs of levonorgestrel-releasing intrauterine system or hysterectomy in the treatment of menorrhagia: a 10-year randomized controlled trial. Am J Obstet Gynecol 209(6):535 e1-e14CrossRefPubMed Heliövaara-Peippo S, Hurskainen R, Teperi J, Aalto AM, Grénman S, Halmesmäki K et al (2013) Quality of life and costs of levonorgestrel-releasing intrauterine system or hysterectomy in the treatment of menorrhagia: a 10-year randomized controlled trial. Am J Obstet Gynecol 209(6):535 e1-e14CrossRefPubMed
7.
Zurück zum Zitat Marjoribanks J, Lethaby A, Farquhar C (2006) Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev 2:Cd003855 Marjoribanks J, Lethaby A, Farquhar C (2006) Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev 2:Cd003855
8.
Zurück zum Zitat Halmesmäki K, Hurskainen R, Teperi J, Grenman S, Kivelä A, Kujansuu E et al (2007) The effect of hysterectomy or levonorgestrel-releasing intrauterine system on sexual functioning among women with menorrhagia: a 5-year randomised controlled trial. BJOG 114(5):563–568CrossRefPubMed Halmesmäki K, Hurskainen R, Teperi J, Grenman S, Kivelä A, Kujansuu E et al (2007) The effect of hysterectomy or levonorgestrel-releasing intrauterine system on sexual functioning among women with menorrhagia: a 5-year randomised controlled trial. BJOG 114(5):563–568CrossRefPubMed
9.
Zurück zum Zitat Podzolkova N, Tatarchuk T, Doshchanova A, Eshimbetova G, Pexman-Fieth C (2016) Dydrogesterone treatment for menstrual-cycle regularization in routine clinical practice: a multicenter observational study. Gynecol Endocrinol 32(3):246–249CrossRefPubMed Podzolkova N, Tatarchuk T, Doshchanova A, Eshimbetova G, Pexman-Fieth C (2016) Dydrogesterone treatment for menstrual-cycle regularization in routine clinical practice: a multicenter observational study. Gynecol Endocrinol 32(3):246–249CrossRefPubMed
10.
Zurück zum Zitat Gorgen H, Api M, Akça A, Cetin A (2009) Use of the levonorgestrel-IUS in the treatment of menorrhagia: assessment of quality of life in Turkish users. Arch Gynecol Obstet 279:835–840CrossRefPubMed Gorgen H, Api M, Akça A, Cetin A (2009) Use of the levonorgestrel-IUS in the treatment of menorrhagia: assessment of quality of life in Turkish users. Arch Gynecol Obstet 279:835–840CrossRefPubMed
11.
Zurück zum Zitat Bastianelli C, Farris M, Benagiano G (2011) Use of the levonorgestrel-releasing intrauterine system, quality of life and sexuality. Experience in an Italian family planning center. Contracept 84(4):402–8CrossRef Bastianelli C, Farris M, Benagiano G (2011) Use of the levonorgestrel-releasing intrauterine system, quality of life and sexuality. Experience in an Italian family planning center. Contracept 84(4):402–8CrossRef
12.
Zurück zum Zitat Gupta J, Kai J, Middleton L, Pattison H, Gray R, Daniels J (2013) Levonorgestrel intrauterine system versus medical therapy for menorrhagia. N Engl J Med 368(2):128–137CrossRefPubMed Gupta J, Kai J, Middleton L, Pattison H, Gray R, Daniels J (2013) Levonorgestrel intrauterine system versus medical therapy for menorrhagia. N Engl J Med 368(2):128–137CrossRefPubMed
13.
Zurück zum Zitat Yalçın Bahat P, Yücel B, Yuksel Ozgor B, Kadiroğulları P, Topbas Selçuki NF, Çakmak K et al (2022) The effect of dydrogesterone on sexual function in endometriosis. J Obstet Gynaecol 42(5):1276–1279CrossRefPubMed Yalçın Bahat P, Yücel B, Yuksel Ozgor B, Kadiroğulları P, Topbas Selçuki NF, Çakmak K et al (2022) The effect of dydrogesterone on sexual function in endometriosis. J Obstet Gynaecol 42(5):1276–1279CrossRefPubMed
14.
Zurück zum Zitat Backman T (2004) Benefit-risk assessment of the levonorgestrel intrauterine system in contraception. Drug Saf 27(15):1185–1204CrossRefPubMed Backman T (2004) Benefit-risk assessment of the levonorgestrel intrauterine system in contraception. Drug Saf 27(15):1185–1204CrossRefPubMed
15.
Zurück zum Zitat Mittermeier T, Farrant C, Wise MR (2020) Levonorgestrel-releasing intrauterine system for endometrial hyperplasia. Cochrane Database Syst Rev 9(9):Cd012658PubMed Mittermeier T, Farrant C, Wise MR (2020) Levonorgestrel-releasing intrauterine system for endometrial hyperplasia. Cochrane Database Syst Rev 9(9):Cd012658PubMed
16.
Zurück zum Zitat Goshtasebi A, Moukhah S, Gandevani SB (2013) Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Arch Gynecol Obstet 288(5):1055–1060CrossRefPubMed Goshtasebi A, Moukhah S, Gandevani SB (2013) Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Arch Gynecol Obstet 288(5):1055–1060CrossRefPubMed
Metadaten
Titel
A comparison of the effects of oral dydrogesterone and levonorgestrel-releasing intrauterine device on quality of life and sexual function in patients with abnormal uterine bleeding
verfasst von
Ruken Abul
Nura Fitnat Topbas Selcuki
Ozan Karadeniz
Pınar Yalçın Bahat
Publikationsdatum
27.12.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 2/2024
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-023-07315-y

Weitere Artikel der Ausgabe 2/2024

Archives of Gynecology and Obstetrics 2/2024 Zur Ausgabe

Images in Obstetrics and Gynecology

Ogilvie syndrome after cesarean section

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.